CA
NZ
UK
AU
IND
US
● The move followed the company's second-quarter 2026 update.
● EyePoint Pharmaceuticals rebounded roughly 12% as bargain hunters and reassessing bulls stepped back into the stock.
●Revenuereached $64.1 million, up 48% year over year.
● Aclaris Therapeutics rose about 6.5%, putting the clinical-stage immuno-inflammation biotech back on traders' breakout watchlists.
● iSpecimen rose about 8.8% on Wednesday, adding to the choppy, high-amplitude trading that has defined the stock.
● The company's aprevo personalized spine implant is the centerpiece of its commercial strategy.
● Eikon Therapeutics rallied roughly 11%, drawing renewed interest to one of the higher-profile biotech IPOs of 2026.
● Harvard Bioscience climbed roughly 7.2%, extending a rebound in the small-cap life-science instruments maker.
● Kura Oncology shares rose about 9.3% this week, pulling the AML-focused biotech back onto the momentum radar.
● Adial Pharmaceuticals jumped about 9.2%, extending a sharp, volatile move familiar for the tiny Charlottesville, Virginia drug developer.
Please wait processing your request...